Fintel reports that on April 10, 2025, Mizuho initiated coverage of Embecta (NasdaqGS:EMBC) with a Neutral recommendation.

Mizuho initiated coverage of Embecta (EMBC) with a Neutral rating and $15 price target The firm says its rating balances the company’s ...

KLP Kapitalforvaltning AS bought a new stake in Embecta Corp. (NASDAQ:EMBC – Free Report) during the 4th quarter, according ...

In addition, Embecta's stockholders ratified the appointment of Ernst & Young LLP with 52,811,690 votes for, 90,619 against, and 40,661 abstentions. Furthermore, the ...

Embecta (Nasdaq:EMBC) announced a new publication introducing best practices for insulin injection techniques and education.

Embecta (EMBC) announced a new publication in the Mayo Clinic Proceedings. The publication introduces the FITTER Forward Expert ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

The Financial Times reports today that BD (NYSE: BDX) began discussions with competitors for the sale of its Life Sciences ...

Vanguard Group Inc. increased its holdings in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) by 0.4% in the fourth quarter, according to the company in its most recent filing with the SEC.

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application.

embecta leveraged World Diabetes Day for the launch of its All In campaign to establish itself as a pure player in diabetes management, foster access to diabetes education for healthcare professionals ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...